Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 8/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391705 | 0.90 | PTGS2 (0.65) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL6393310 | 0.89 | PTGS2 (0.72) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL5594144 | 0.89 | PTGS2 (0.72) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL11687773 | 0.83 | GRM5 (0.51) | GABRA2GABRB2PTGS2CNR1MAP4K4 | |
| SCHEMBL6429757 | 0.82 | CNR1 (0.62) | CNR1 | |
| SCHEMBL476456 | 0.81 | GABRA2 (0.63) | GABRA2GABRB2PTGS2CNR1PTGS1 | |
| SCHEMBL5419709 | 0.81 | GABRA2 (0.62) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL6389062 | 0.79 | PTGS2 (0.65) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL6393712 | 0.79 | PTGS2 (0.65) | GABRA2GABRB2PTGS2PTGS1 | |
| SCHEMBL6390052 | 0.76 | PTGS2 (0.74) | GABRA2GABRB2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | GABRA2 981/4885GABRB2 622/4885PTGS2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.